Business Context and Reporting Period
Company: OPKO Health, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 23, 2013
Event: Entry into a Material Definitive Agreement (Merger Agreement) with PROLOR Biotech, Inc.
Key Financial Metrics
This filing is a current report regarding a corporate transaction and does not contain periodic financial statements (e.g., revenue, profit, cash flow, or margins). The following transaction-specific financial terms are disclosed:
- Exchange Ratio: Each outstanding share of PROLOR common stock will be converted into the right to receive 0.9951 shares of OPKO common stock.
- Termination Fees:
- Standard termination fee: $9,600,000 (payable by either party under certain circumstances).
- Enhanced termination fee: $14,400,000 (payable by PROLOR to OPKO under certain circumstances).
- Tax Status: The Merger is intended to qualify as a reorganization for federal income tax purposes.
Material Changes and Transaction Details
OPKO Health, Inc. and PROLOR Biotech, Inc. entered into an Agreement and Plan of Merger. Under the agreement, a newly formed, wholly-owned subsidiary of OPKO will merge with and into PROLOR, with PROLOR surviving as a wholly-owned subsidiary of OPKO.
- Expected Closing: Second half of 2013.
- Conditions to Closing: Includes stockholder approvals for both companies, regulatory and antitrust approvals (including Hart-Scott-Rodino), Israeli Securities Authority clearances, SEC effectiveness of the registration statement, and NYSE listing approval.
- Go-Shop Provision: PROLOR has the right to solicit competing proposals through June 2, 2013, and may continue discussions until June 22, 2013, with parties submitting superior proposals.
- Related Party Transactions: Significant overlap in leadership and ownership exists. Phillip Frost, M.D. (OPKO Chairman/CEO) is PROLOR's Chairman. Jane H. Hsiao, Ph.D., M.B.A. (OPKO Vice Chairman/CTO) and Steven D. Rubin (OPKO EVP) are directors of PROLOR. These individuals abstained from the Board approvals.
Guidance, Outlook, and Risks
Outlook: The transaction is expected to close in the second half of 2013, subject to the conditions listed above.
Risks and Contingencies:
- Regulatory Risk: Completion is contingent on various regulatory approvals, including antitrust and foreign securities authorities.
- Termination Risk: The agreement includes termination rights for both parties, which could result in the payment of termination fees.
- Competing Proposals: The "go-shop" provision allows PROLOR to seek superior proposals, which could alter or terminate the current agreement.
- Stockholder Approval: The deal requires approval from stockholders of both OPKO and PROLOR.
Management Commentary: The filing directs investors to the upcoming Joint Proxy Statement/Prospectus (Form S-4) for detailed information regarding the transaction and participant interests.
Investor Verification Checklist
- Verify the final terms and exchange ratio in the definitive Joint Proxy Statement/Prospectus (Form S-4).
- Monitor the status of regulatory approvals, specifically the Hart-Scott-Rodino Act and Israeli Securities Authority clearances.
- Track the outcome of the "go-shop" period ending June 2, 2013, for any competing proposals.
- Confirm the results of the stockholder votes for both OPKO and PROLOR.
- Review the related party disclosures to understand the extent of shared ownership and potential conflicts of interest.